BioTech IP Review

Patent Number: US 12,338,436 B2
Filing Date: June 28, 2019
Issue Date: June 24, 2025
Assignee: Editas Medicine, Inc.
Inventors: Sam Saccomano, Stacy Capehart, Bruce Eaton, Karin Zemski Berry

---

What This Patent Covers

This granted U.S. patent protects synthetic guide RNA (gRNA) molecules and related compositions and methods used in CRISPR‑based genome editing systems. Such guide molecules are critical components of CRISPR editing because they direct the nuclease (e.g., Cas9 or Cas12a) to the specific genomic sequence to be modified.

Key aspects of the invention include:

• High‑purity synthetic guide RNAs: The technology provides methods for synthesizing unimolecular guide RNA constructs with minimal contaminating species (e.g., truncation products), improving editing precision and efficiency in therapeutic applications.
• Guide molecule compositions: It describes optimized compositions of guide RNAs that enhance performance for in vivo and ex vivo editing — crucial for clinical gene editing medicines.
• Methods of use: The patent covers methods for using these synthetic guides in CRISPR systems to direct targeted genomic alterations in cells, which can be applied across a range of therapeutic indications.

Because guide RNAs are central to precise and efficient CRISPR editing, improvements in their design and manufacture are enabling technology for Editas’s pipeline of gene‑editing medicines.

---

Why This Patent Is Important

1) Core Technology for CRISPR‑based Therapeutics
Guide RNAs are essential to CRISPR gene editing — they tell the editing nuclease where to cut or modify DNA. Patents covering high‑quality synthetic guide molecules provide Editas with strong rights over a key enabling technology used across multiple gene‑editing programs.

2) Broad Therapeutic Applicability
This patent has relevance across all CRISPR‑based therapeutic programs — including Editas’s in‑vivo candidates (e.g., HSC or liver editing) and other potential clinical and preclinical gene editing medicines. Such broad applicability increases its commercial importance.

3) Supports Competitive IP Position
In the competitive gene editing landscape, owning patents on foundational components like guide RNA design and composition strengthens Editas’s intellectual property moat and provides leverage in licensing, collaborations, or potential enforcement.

4) Patent Value Into the Future
Although filed in 2019, issuing in mid‑2025 means the patent protections will extend for many years, supporting Editas’s long‑term strategic development of CRISPR therapies.